Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma

The development of resistance to trastuzumab in HER2‐positive gastroesophageal cancer remains a problem. The use of dual HER2 blockade to overcome this is a therapeutic strategy that should be researched more extensively.

Detalles Bibliográficos
Autores principales: Cheong, E. Von, Ho, Gwo Fuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077340/
https://www.ncbi.nlm.nih.gov/pubmed/33936677
http://dx.doi.org/10.1002/ccr3.4009
_version_ 1783684864436862976
author Cheong, E. Von
Ho, Gwo Fuang
author_facet Cheong, E. Von
Ho, Gwo Fuang
author_sort Cheong, E. Von
collection PubMed
description The development of resistance to trastuzumab in HER2‐positive gastroesophageal cancer remains a problem. The use of dual HER2 blockade to overcome this is a therapeutic strategy that should be researched more extensively.
format Online
Article
Text
id pubmed-8077340
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80773402021-04-29 Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma Cheong, E. Von Ho, Gwo Fuang Clin Case Rep Case Reports The development of resistance to trastuzumab in HER2‐positive gastroesophageal cancer remains a problem. The use of dual HER2 blockade to overcome this is a therapeutic strategy that should be researched more extensively. John Wiley and Sons Inc. 2021-03-05 /pmc/articles/PMC8077340/ /pubmed/33936677 http://dx.doi.org/10.1002/ccr3.4009 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Cheong, E. Von
Ho, Gwo Fuang
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
title Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
title_full Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
title_fullStr Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
title_full_unstemmed Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
title_short Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
title_sort dual her2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077340/
https://www.ncbi.nlm.nih.gov/pubmed/33936677
http://dx.doi.org/10.1002/ccr3.4009
work_keys_str_mv AT cheongevon dualher2blockadewithlapatinibandtrastuzumabincombinationwithchemotherapyinmetastaticgastroesophagealadenocarcinoma
AT hogwofuang dualher2blockadewithlapatinibandtrastuzumabincombinationwithchemotherapyinmetastaticgastroesophagealadenocarcinoma

Ejemplares similares